Flexion Therapeutics, which is developing sustained-release injectable pain therapies for osteoarthritis, raised $65 million by offering 5.0 million shares at $13, within the range of $12 to $14. Flexion Therapeutics plans to list on the NASDAQ under the symbol FLXN. Flexion Therapeutics initially filed confidentially on 8/2/2013. BMO Capital Markets and Wells Fargo Securities acted as lead managers on the deal.
